Melissa Natavio1, Frank Z Stanczyk2, Emilie A G Molins3, Anita Nelson2, William J Jusko3. 1. Department of Obstetrics and Gynecology, Los Angeles, California; Keck School of Medicine, University of Southern California, Los Angeles, California. Electronic address: natavio@usc.edu. 2. Department of Obstetrics and Gynecology, Los Angeles, California; Keck School of Medicine, University of Southern California, Los Angeles, California. 3. Department of Pharmaceutical Sciences, State University of New York at Buffalo, Buffalo, New York.
Abstract
OBJECTIVE: To assess the pharmacokinetics (PK) of levonorgestrel after 1.5 mg oral doses (LNG-EC) in women with normal, obese and extremely obese body mass index (BMI). STUDY DESIGN: The 1.5 mg LNG dose was given to healthy, reproductive-age, ovulatory women with normal BMI (mean 22.0), obese (mean 34.4), and extremely obese (mean 46.6 kg/m2) BMI. Total serum LNG was measured over 0 to 96 h by radioimmunoassay while free and bioavailable LNG were calculated. The maximum concentration (Cmax), time to maximum concentration (Tmax), and area under the curve (AUC) of LNG were assessed. Pharmacokinetic parameters calculated included half-life (t1/2), clearance (CL) and volume of distribution (Vss). RESULTS: Ten normal-BMI, 11 obese-BMI, 5 extremely obese-BMI women were studied. After LNG-EC, mean total LNG metrics were lower in the obese and extremely obese groups compared to normal (Cmax 10.5 and 10.5 versus 16.2 ng/mL, both p<.01; AUC 208 and 197 versus 360 h × ng/mL, both p<.05). Mean bioavailable LNG Cmax was lower in obese (7.03 ng/mL, p<.05) and extremely obese (7.53 ng/ml, p=.198) compared to normal BMI (9.39 ng/mL). Mean bioavailable LNG AUC values were lower in obese and extremely obese compared to normal (131.6 and 127.5 vs 185.0 h × ng/mL, p<.05 for both). CONCLUSIONS: Obese and extremely obese women were exposed to lower total and bioavailable LNG than normal BMI women. IMPLICATIONS: Lower 'bioavailable' (free plus albumin bound) LNG AUC in obese women may play a role in the purported reduced efficacy of LNG-EC in obese users.
OBJECTIVE: To assess the pharmacokinetics (PK) of levonorgestrel after 1.5 mg oral doses (LNG-EC) in women with normal, obese and extremely obese body mass index (BMI). STUDY DESIGN: The 1.5 mg LNG dose was given to healthy, reproductive-age, ovulatory women with normal BMI (mean 22.0), obese (mean 34.4), and extremely obese (mean 46.6 kg/m2) BMI. Total serum LNG was measured over 0 to 96 h by radioimmunoassay while free and bioavailable LNG were calculated. The maximum concentration (Cmax), time to maximum concentration (Tmax), and area under the curve (AUC) of LNG were assessed. Pharmacokinetic parameters calculated included half-life (t1/2), clearance (CL) and volume of distribution (Vss). RESULTS: Ten normal-BMI, 11 obese-BMI, 5 extremely obese-BMI women were studied. After LNG-EC, mean total LNG metrics were lower in the obese and extremely obese groups compared to normal (Cmax 10.5 and 10.5 versus 16.2 ng/mL, both p<.01; AUC 208 and 197 versus 360 h × ng/mL, both p<.05). Mean bioavailable LNG Cmax was lower in obese (7.03 ng/mL, p<.05) and extremely obese (7.53 ng/ml, p=.198) compared to normal BMI (9.39 ng/mL). Mean bioavailable LNG AUC values were lower in obese and extremely obese compared to normal (131.6 and 127.5 vs 185.0 h × ng/mL, p<.05 for both). CONCLUSIONS: Obese and extremely obese women were exposed to lower total and bioavailable LNG than normal BMI women. IMPLICATIONS: Lower 'bioavailable' (free plus albumin bound) LNG AUC in obese women may play a role in the purported reduced efficacy of LNG-EC in obese users.
Authors: Nathalie Kapp; Jean Louis Abitbol; Henri Mathé; Bruno Scherrer; Hélène Guillard; Erin Gainer; André Ulmann Journal: Contraception Date: 2014-11-08 Impact factor: 3.375
Authors: Piyapa Praditpan; Angie Hamouie; Cale N Basaraba; Renu Nandakumar; Serge Cremers; Anne R Davis; Carolyn L Westhoff Journal: Contraception Date: 2017-01-23 Impact factor: 3.375
Authors: Claes Ohlsson; Henri Wallaschofski; Kathryn L Lunetta; Lisette Stolk; John R B Perry; Annemarie Koster; Ann-Kristin Petersen; Joel Eriksson; Terho Lehtimäki; Ilpo T Huhtaniemi; Geoffrey L Hammond; Marcello Maggio; Andrea D Coviello; Luigi Ferrucci; Margit Heier; Albert Hofman; Kate L Holliday; John-Olov Jansson; Mika Kähönen; David Karasik; Magnus K Karlsson; Douglas P Kiel; Yongmei Liu; Osten Ljunggren; Mattias Lorentzon; Leo-Pekka Lyytikäinen; Thomas Meitinger; Dan Mellström; David Melzer; Iva Miljkovic; Matthias Nauck; Maria Nilsson; Brenda Penninx; Stephen R Pye; Ramachandran S Vasan; Martin Reincke; Fernando Rivadeneira; Abdelouahid Tajar; Alexander Teumer; André G Uitterlinden; Jagadish Ulloor; Jorma Viikari; Uwe Völker; Henry Völzke; H Erich Wichmann; Tsung-Sheng Wu; Wei Vivian Zhuang; Elad Ziv; Frederick C W Wu; Olli Raitakari; Anna Eriksson; Martin Bidlingmaier; Tamara B Harris; Anna Murray; Frank H de Jong; Joanne M Murabito; Shalender Bhasin; Liesbeth Vandenput; Robin Haring Journal: PLoS Genet Date: 2011-10-06 Impact factor: 5.917
Authors: Anna L Goldman; Shalender Bhasin; Frederick C W Wu; Meenakshi Krishna; Alvin M Matsumoto; Ravi Jasuja Journal: Endocr Rev Date: 2017-08-01 Impact factor: 25.261